Evidence map›Paper›PMID 28751841›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2017

Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pharmacologic pre-treatment for patients undergoing myocardial revascularization procedures.

Roberto Caporale, Giovanna Geraci, Michele Massimo Gulizia, Mauro Borzi, Furio Colivicchi, A Menozzi, Giuseppe Musumeci, Marino Scherillo, Antonietta Ledda, Giuseppe Tarantini and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Roberto CaporaleInterventional Cardiology Department, Ospedale Civile dell'Annunziata, Via Migliori 1, 87100 Cosenza, Italy.
Giovanna GeraciCardiology Department, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Michele Massimo GuliziaCardiology Department, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania, Italy.
Mauro BorziCardiology and Interventional Cardiology Department, Università di Tor Vergata, Roma, Italy.
Furio ColivicchiCardiology Department, Ospedale San Filippo Neri, Roma, Italy.
A MenozziCardiology Unit, Azienda Ospedaliero-Universitaria, Parma, Italy.
Giuseppe MusumeciCardiology Department, Ospedale Santa Croce e Carle, Cuneo, Italy.
Marino ScherilloInterventional Cardiology, A.O. G. Rummo, Benevento, Italy.
Antonietta LeddaCardiology Department, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Giuseppe TarantiniCardiological Sciences, Thoracic and Vascular Department, Università degli Studi, Padova, Italy.
Piersilvio GeromettaHeart Surgery Department, Istituto Humanitas Gavazzeni, Bergamo, Italy.
Giancarlo CasoloCardiology Department, Nuovo Ospedale Versilia, Lido di Camaiore, Lucca, Italy.
Dario FormigliInterventional Cardiology, A.O. G. Rummo, Benevento, Italy.
Francesco RomeoCardiology and Interventional Cardiology Department, Università di Tor Vergata, Roma, Italy.
Roberto Di BartolomeoHeart Surgery Unit, Ospedale Policlinico S. Orsola-Malpighi, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The wide availability of effective drugs in reducing cardiovascular events together with the use of myocardial revascularization has greatly improved the prognosis of patients with coronary artery disease. The combination of antithrombotic drugs to be administered before the knowledge of the coronary anatomy and before the consequent therapeutic strategies, can allow to anticipate optimal treatment, but can also expose the patients at risk of bleeding that, especially in acute coronary syndromes, can significantly weigh on their prognosis, even more than the expected theoretical benefit. In non ST-elevation acute coronary syndromes patients in particular, we propose a 'selective pre-treatment' with P2Y

Indexed as

Acute coronary syndromesAnticoagulant agentsAntiplatelet agentsCoronary artery diseaseHaemorrhageMyocardial revascularization

Identifiers

PMID28751841
PMCPMC5520758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.